← Back to Search

Procedure

Endoscopic-Assisted Vitrectomy for Corneal Transplant Complications (KPro-HP-Endo Trial)

N/A
Recruiting
Led By Mona Harissi-Dagher, MD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged from 18 to 80 years old
Pars plana vitrectomy candidate
Must not have
Aged less than 18 or more than 80 years old
Inability to give informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether performing a complete vitrectomy at the same time as KPro surgery, assisted by endoscopy, reduces postoperative complications.

Who is the study for?
This trial is for adults aged 18 to 80 who are candidates for a corneal transplant using the Boston keratoprosthesis type 1 and also need vitrectomy surgery. Participants must be able to follow the study's procedures over time. It's not open to those under 18 or over 80, anyone unable to consent, or patients needing repeat surgeries of these types.
What is being tested?
The study tests if peeling the anterior hyaloid membrane with endoscopic assistance during corneal transplant surgery can reduce complications like glaucoma and retinal detachment compared to doing this step after the transplant without endoscopy.
What are the potential side effects?
Potential side effects may include issues related to eye surgery such as increased eye pressure, infection risk, inflammation, vision changes, or detachment of the retina.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 80 years old.
Select...
I am a candidate for eye surgery to remove the vitreous gel.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am either younger than 18 or older than 80.
Select...
I am unable to understand and agree to the study's details.
Select...
I have had more than one vitrectomy surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of glaucoma development
Rate of retinal detachment
Rate of retroprosthetic membrane formation
Secondary study objectives
Change of visual acuity
Proportion of participants requiring glaucoma surgery
Proportion of patients with thinning of the nerve fiber layer
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with KPro, PPV, and endoscopyExperimental Treatment1 Intervention
Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,360 Total Patients Enrolled
Mona Harissi-Dagher, MDPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
3 Previous Clinical Trials
200 Total Patients Enrolled

Media Library

Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04337944 — N/A
Corneal Transplant Research Study Groups: Patients with KPro, PPV, and endoscopy
Corneal Transplant Clinical Trial 2023: Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy Highlights & Side Effects. Trial Name: NCT04337944 — N/A
Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04337944 — N/A
~4 spots leftby Nov 2025